These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 23714158)

  • 21. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid-bound sialic acid (LSA) in liver diseases of different etiologies.
    Chrostek L; Cylwik B; Panasiuk A; Brodowska-Adamusiak D; Gruszewska E
    Ann Hepatol; 2011; 10(2):150-4. PubMed ID: 21502676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.
    Beyoğlu D; Idle JR
    Metabolites; 2020 Jan; 10(2):. PubMed ID: 32012846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease.
    Younossi ZM; Stepanova M; Al Shabeeb R; Eberly KE; Shah D; Nguyen V; Ong J; Henry L; Alqahtani SA
    Hepatol Commun; 2024 Jan; 8(1):. PubMed ID: 38126928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.
    Berkan-Kawińska A; Piekarska A
    Curr Med Res Opin; 2020 Feb; 36(2):235-243. PubMed ID: 31631714
    [No Abstract]   [Full Text] [Related]  

  • 26. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
    Meringer H; Shibolet O; Deutsch L
    World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased Risk of Death in First Year After Liver Transplantation Among Patients With Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies.
    Nagai S; Collins K; Chau LC; Safwan M; Rizzari M; Yoshida A; Abouljoud MS; Moonka D
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2759-2768.e5. PubMed ID: 31004758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The identification of stem cells in human liver diseases and hepatocellular carcinoma.
    Oliva J; French BA; Qing X; French SW
    Exp Mol Pathol; 2010 Jun; 88(3):331-40. PubMed ID: 20080086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nuclear magnetic resonance based metabolomics and liver diseases: Recent advances and future clinical applications.
    Amathieu R; Triba MN; Goossens C; Bouchemal N; Nahon P; Savarin P; Le Moyec L
    World J Gastroenterol; 2016 Jan; 22(1):417-26. PubMed ID: 26755887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
    Huang W; Zhang XX
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):157-160. PubMed ID: 28297806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
    Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.